Health Canada approved BELKYRA™, an injectable drug for fullness under the chin (a “double chin”), on July 27, 2015, three months after its approval by the FDA in the United States under the label “KYBELLA.”
The prescription treatment has the ability to re-define the jawline, improving the profile of moderate to severe fat below the chin (medically known as “submental fat”). Submental fullness is a common condition that is influenced by factors such as genetics, aging and weight gain. Often resistant to diet and exercise, it can create an illusion of someone being heavy or overweight – even when the rest of their body is not.
Rare Non-Invasive Treatment
This is the first non-invasive procedure focussed on treating submental fat. Prior to BELKYRA, patients had to turn to surgery or skin tightening devices such as Thermage.
Visible results can be seen in two to four treatments. Treatment should only be provided by a licensed medical professional who understands how to not only correctly inject the drug, but who also understands any risks associated with the treatment.
How Does It Work?
BELKYRA™ consists of a formulation of deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown and absorption of fat. Once injected into subcutaneous fat, BELKYRA™ causes the destruction of fat cells, disabling the ability to store or accumulate fat.
BELKYRA is clinically supported by over 20 clinical studies with more that 2,600 patients worldwide of which 1,600 were treated with BELKYRA [source].